Vaccines are the mainstay of care in the COVID-19 pandemic. However, patients may still become infected and need treatment options. Two studies have evaluated the role of inhaled budesonide for the early treatment of outpatient COVID-19 infections. Can budesonide hasten the resolution of symptoms or prevent hospitalizations?

Redeem your CPE or CME credit here!

References and resources:
Ramakrishnan S, Nicolau DV, Langford B, et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. The Lancet Respiratory Medicine. April 2021. doi:10.1016/s2213-2600(21)00160-0

Yu L-M, Bafadhel M, Dorward J, et al. Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial. medRxiv. Published online January 1, 2021:2021.04.10.21254672. doi:10.1101/2021.04.10.21254672

Continuing Education Information:
Learning Objective: Identify the appropriate patient population for inhaled budesonide in the treatment of COVID-19
0.05 CEU | 0.5 Hrs
ACPE UAN: 0107-0000-21-228-H01-P
0.50 AMA PRA Category 1 CreditsTM.(the TM needs to be super scripted)
Initial release date: 6/29/21
Expiration date: 6/29/22
Complete CPE & CME details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram